ClinicalTrials.gg

TargetBeta

PIK3R3

phosphoinositide-3-kinase regulatory subunit 3 · also p55 · SH2 domain containing

3 programs in company-led studies act on PIK3R3, from 3 companies: 1 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
gedatolisibrulePfizerphase 393 runningMTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R5ChEMBL
paxalisibruleKazia Therapeuticsphase 241 runningPIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R5ChEMBL
Autologous Anti-DLL3 CAR/CARD11-PIK3R3 Fusion Transgene-expressing T-cells ML261ruleMoonlight Biophase 111 runningCARD11, DLL3NCIt

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.